Andrew Yee, MD, discusses the phase 3 CANDOR trial in relapsed/refractory multiple myeloma.
In the phase 3 CANDOR trial, investigators examined the combination of carfilzomib (Kyprolis), daratumumab (Darzalex), and dexamethasone versus carfilzomib/dexamethasone alone in patients with relapsed/refractory multiple myeloma, says Yee. One thing to note is that this trial was for patients who received 1 to 3 prior lines of treatment, and the carfilzomib regimen was administered on a twice-a-week schedule.
Results from the trial showed that the triplet regimen resulted in significant improvement in high-quality responses, as well as a significant improvement in progression-free survival (PFS) when compared with the doublet regimen, adds Ye. The median PFS was not reached for the triplet arm versus 15.8 months for the doublet arm (HR, 0.63; 95% CI, 0.46-0.85; P = .0014).
Like all treatments that are available, approaches must be tailored to patients and their preferences, adds Ye. For patients who might have trouble obtaining pomalidomide (Pomalyst) due to, for example, financial issues, this triplet regimen can serve as an excellent option without too much out-of-pocket cost, concludes Yee.